

The CIMT Immunoguiding Program (CIP)



CIP - Committee



C. Gouttefangeas



S. Van der Burg




C. Britten



C. Ottensmeier



M. Welters



Today's focus

- Provide immediate feed-back about performance relative to the group - „*Quality Assurance*“.
- Use the collected data to systematically identify sources of variation and quantify their impact on test results - „*Protocol Optimization*“.
- Use the collected data to deduce protocol recommendations. - „*Protocol Optimization*“.

T-cell monitoring - The Challenges



High variation between protocols

No comparability of results from different labs

Lack of Validation / No standards



(Justified) Skepticism towards results from used tests

Difficulty to show correlation with clinical events

Proficiency Panel Programs can help to (partially) solve these problems.



Networks such as CIMT, CVC or iSBTc can help to communicate

Has to be addressed within clinical trial program

The CIMT Immunoguiding Program (CIP)



www.c-imt.org

Acknowledgements

• CIMT (Executive Board)

- C. Huber
- C.J.M. Melief
- G. Schuler
- H.G. Rammensee
- P. Johnson
- P. Walden
- U. Kalinke



• Collaborators

- CVC-CRI (S. Janetzki, M. Kalos)
- Helmholtz Alliance (D. Schendel, C. Falk)
- R. Stebbings (NIBSC, UK)
- C.Chan (Duke, Durham, USA)
- L. Price (New York, USA)
- Z. Moodie (FHRC, Seattle, USA)

• Support / Research Grant

- Wallace Coulter Foundation



Thank you for the invitation !

iSBTc-FDA-NCI Workshop on Prognostic and Predictive Immunologic Biomarkers in Cancer

- L. Butterfield
- M. Disis
- B. Fox
- S. Khleif
- M. Thurin
- F. Marincola

Save the Date !

CIMT Annual Meeting 2010

Date: May 26th - 28th 2010

Location: Mainz, Germany

Info: www.c-imt.org

Scientific Secretary: S. Kreiter

CIP supports MIATA !

Visit: www.miataproject.org

